Cresset BioMolecular Discovery has launched FieldStere, which is a software product that enables medicinal chemists to enrich their shortlist of drug candidates with structurally diverse compounds that share the same desired biological activity (bioisosteres).
FieldStere allows the fine-tuning of the resulting bioisosteres to enhance potency and specificity whilst removing undesirable ADME and physical properties.
The new FieldStere product builds on Cresset’s proprietary Field technology, which describes chemical structures in terms of the surface properties of the whole molecule. These determine, much more accurately than existing tools, how a compound will interact with other molecules.
These non-obvious compounds increase the medicinal chemistry repertoire and can represent novel product opportunities unprotected by existing patents. As a result, FieldStere has application in the development of patent strategy for the protection of new molecular entities, identifying follow-on compounds as marketed products come off patent and lead optimisation of new drugs.
FieldStere will be sold through Cresset’s sales operations and offered as part of a leveraged service offering to companies that need to access specialist chemistry services.